Tumor necrosis factor receptor
From Proteopedia
(Difference between revisions)
| Line 19: | Line 19: | ||
* '''TNFRSF 13C''' is called '''BAFF receptor''';<br /> | * '''TNFRSF 13C''' is called '''BAFF receptor''';<br /> | ||
* '''TNFRSF 14''' is called '''LIGHT''';<br /> | * '''TNFRSF 14''' is called '''LIGHT''';<br /> | ||
| - | * '''TNFRSF 16''' is called '''Low-affinity nerve growth factor receptor''';<br /> | + | * '''TNFRSF 16''' is called '''Low-affinity nerve growth factor receptor; p75NTR; p75 neurotrophin receptor''';<br /> |
* '''TNFRSF 18''' is called '''GITRL''';<br /> | * '''TNFRSF 18''' is called '''GITRL''';<br /> | ||
* '''TNFRSF 21''' is called '''Dr6''';<br /> | * '''TNFRSF 21''' is called '''Dr6''';<br /> | ||
| Line 144: | Line 144: | ||
**[[4kgq]], [[4kgg]] – hTNFSF-14 extracellular domain (mutant) + DCR3 <BR /> | **[[4kgq]], [[4kgg]] – hTNFSF-14 extracellular domain (mutant) + DCR3 <BR /> | ||
| - | *Tumor necrosis factor receptor superfamily-16 (Low-affinity nerve growth factor receptor) | + | *Tumor necrosis factor receptor superfamily-16 (Low-affinity nerve growth factor receptor; p75NTR; p75 neurotrophin receptor) |
**[[4f42]], [[4f44]] – hTNFRSF-16 death domain<br /> | **[[4f42]], [[4f44]] – hTNFRSF-16 death domain<br /> | ||
**[[2n97]] – hTNFRSF-16 death domain - NMR<br /> | **[[2n97]] – hTNFRSF-16 death domain - NMR<br /> | ||
| + | **[[2mic]] – rTNFRSF-16 transmembrane domain – rat - NMR<br /> | ||
| + | **[[2mjo]] – rTNFRSF-16 transmembrane domain (mutant) - NMR<br /> | ||
**[[1sg1]], [[3ij2]] – hTNFRSF-16 + beta nerve growth factor<br /> | **[[1sg1]], [[3ij2]] – hTNFRSF-16 + beta nerve growth factor<br /> | ||
**[[3buk]] – hTNFRSF-16 + neurotrophin-3<br /> | **[[3buk]] – hTNFRSF-16 + neurotrophin-3<br /> | ||
Revision as of 10:49, 1 January 2019
| |||||||||||
3D structures of tumor necrosis factor receptor
Updated on 01-January-2019
References
- ↑ Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol. 1999;17:331-67. PMID:10358762 doi:http://dx.doi.org/10.1146/annurev.immunol.17.1.331
- ↑ Lopalco G, Rigante D, Vitale A, Frediani B, Iannone F, Cantarini L. Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clin Rheumatol. 2015 Apr;34(4):807-9. doi: 10.1007/s10067-014-2556-8. Epub 2014, Mar 11. PMID:24609716 doi:http://dx.doi.org/10.1007/s10067-014-2556-8
- ↑ Naismith JH, Devine TQ, Kohno T, Sprang SR. Structures of the extracellular domain of the type I tumor necrosis factor receptor. Structure. 1996 Nov 15;4(11):1251-62. PMID:8939750
